3 minute read12/30/2025human
A critical review contrasting robust preclinical data for BPC‑157 and TB‑500 with the absence of high‑quality human RCT evidence, and discussing regulatory and safety concerns around grey‑market peptide use.
What the study reported
Substantial preclinical evidence exists for tissue repair mechanisms, but there are no published randomized controlled trials establishing efficacy and safety in humans; unregulated use and potential risks are emphasized.
How to read it carefully
Synthesis and critique; it identifies evidence gaps rather than providing new experimental results.
Research context only. This brief summarizes a published source and does not establish clinical efficacy, safety, dosing, or suitability for human or veterinary use. Review the original paper before drawing conclusions.
Read the original source · PHYSICAL CULTURE AND SPORT: SCIENTIFIC PERSPECTIVE